These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2895493)

  • 1. What to expect from the newest drugs.
    Rodman MJ
    RN; 1988 Mar; 51(3):59-68, 72-6. PubMed ID: 2895493
    [No Abstract]   [Full Text] [Related]  

  • 2. New drugs of 1987--Part II.
    Hussar DA
    Pa Med; 1988 Oct; 91(10):70-6. PubMed ID: 3067191
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations].
    Ardashev VN; Sokolianskiĭ NV; Bystrov VV
    Klin Med (Mosk); 2000; 78(12):28-30. PubMed ID: 11210347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the GUSTO trial's main conclusion--author's reply. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Stringer KA
    Pharmacotherapy; 1997; 17(5):1043. PubMed ID: 9324198
    [No Abstract]   [Full Text] [Related]  

  • 5. [An open randomized comparative trial of efficacy and safety of selective alpha-adrenoblocker setegis (terazosin) in therapy of patients with chronic bacterial prostatitis].
    Trapeznikova MF; Morozov AP; Dutov VV; Urenkov SB; Pozdniakov KV; Bychkova NV
    Urologiia; 2007; (2):33-7. PubMed ID: 17578197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.
    Eisenberg C
    Pharmacotherapy; 1997; 17(4):850-2. PubMed ID: 9250573
    [No Abstract]   [Full Text] [Related]  

  • 7. An antiemetic drug with a difference.
    Hopkins S
    Nurs Mirror; 1984 May; 158(19):21-2. PubMed ID: 6328454
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tissue plasminogen activator is the best thrombolytic agent].
    Bates E
    Arq Bras Cardiol; 1994 Jul; 63(1):57-8. PubMed ID: 7857215
    [No Abstract]   [Full Text] [Related]  

  • 9. Inter-Nordic variations in sales of medicines.
    Granat M
    Scand J Soc Med Suppl; 1984; 34():21-4. PubMed ID: 6147012
    [No Abstract]   [Full Text] [Related]  

  • 10. Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy.
    Drug Ther Bull; 1984 Feb; 22(3):9-11. PubMed ID: 6321126
    [No Abstract]   [Full Text] [Related]  

  • 11. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding new drugs to treat stroke.
    Barinaga M
    Science; 1996 May; 272(5262):664-6. PubMed ID: 8614822
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrinolytic therapy--plasminogen activator inhibitors].
    Hönigl K; Pilger E; Stark G; Bertuch H
    Vasa Suppl; 1988; 26():103-6. PubMed ID: 3144048
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in serum lipids during drug therapy of hypertension].
    Lohmann FW
    Wien Med Wochenschr; 1982; 132 Spec No 2():6-14. PubMed ID: 6132498
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thrombolytic therapy in acute myocardial infarction].
    Mazza F; Ciappa G; Contiello V; Morra G; Adinolfi L
    Recenti Prog Med; 1987; 78(7-8):377-80. PubMed ID: 3122287
    [No Abstract]   [Full Text] [Related]  

  • 19. [Beta and alpha-adrenoceptor blockers in the planning of anti-hypertensive therapy: recommendations for general practice].
    Bühler FR; Bolli P; Hulthén L; Amann FW
    Ther Umsch; 1981; 38 Suppl():17-23. PubMed ID: 6122284
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.